Table 1.

Guided growth correction rates.

	XLH2*	XLH 3	XLH 4	XLH 6	Kim et al.	Sung et al.
Pharmacological treatment	Burosumab	Burosumab	Burosumab	Conventional
Age at Index Surgery	10y11mo	7y5mo	8y3mo	5y3mo	∅11,8 years	<14 boys, <12 girls
Deformity	Valgus unilateral	Valgus Bilateral	Valgus Bilateral	Varus bilateral	Varus and Valgus	Valgus
No of physis treated	1	4	4	4	154	175
Mean LDFA correction/month		0.8	1.0	0.6		0.71
Mean MPTA correction/month	0.6*	0.8	1.0	0.6		0.40
Correction rate per year	7.2*	9.6	12.0	7.0	6.5	4,8-8,5
Mean MAD correction per month	2.6*	2.9	6.2	2.2
Total Time of Guided Growth	*	15.0	5.0	20.0
	* Guided growth procedure ongoing

Case 6 received conventional therapy at the time of guided growth. Mean correction of degrees per month as well as mean MAD correction in mm per month are listed above. Correction rate per year shows the number of degrees within a year. Reference values for correction rates in children without XLH are shown on the right-hand side (19, 20). Children with XLH with Burosumab treatment show fast correction rate compared to a significantly younger conventional treated child and compared to norm groups in literature.

Cases 2, 3 and 4 underwent temporary hemiepiphysiodesis during Burosumab therapy.

ø = average.